higado
12 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by veronica garay from Melanoma BRAF Inhibitors Review
Scoop.it!

Astra Zeneca/Array Selumetinib Increases PFS modestly Against Metastatic Uveal Melanoma

Astra Zeneca/Array Selumetinib Increases PFS modestly Against Metastatic Uveal Melanoma | higado | Scoop.it
Melanoma Eye Drug NEW YORK, NY — For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye. Results from a multicenter clinical ...

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, June 20, 2014 7:57 AM
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal MelanomaA Randomized Clinical TrialRichard D. Carvajal, MD1,2; Jeffrey A. Sosman, MD3; Jorge Fernando Quevedo, MD4; Mohammed M. Milhem, MD5; Anthony M. Joshua, MBBS, PhD6; Ragini R. Kudchadkar, MD7; Gerald P. Linette, MD, PhD8; Thomas F. Gajewski, MD, PhD9; Jose Lutzky, MD10; David H. Lawson, MD11; Christopher D. Lao, MD12; Patrick J. Flynn, MD13; Mark R. Albertini, MD14; Takami Sato, MD, PhD15; Karl Lewis, MD16; Austin Doyle, MD17; Kristin Ancell, MD3; Katherine S. Panageas, DrPH1; Mark Bluth, MD1; Cyrus Hedvat, MD, PhD1; Joseph Erinjeri, MD, PhD1; Grazia Ambrosini, PhD1; Brian Marr, MD1; David H. Abramson, MD1,2; Mark Andrew Dickson, MD1,2; Jedd D. Wolchok, MD, PhD1,2; Paul B. Chapman, MD1,2; Gary K. Schwartz, MD1,2[+] Author AffiliationsJAMA. 2014;311(23):2397-2405. doi:10.1001/jama.2014.6096.





One hundred one patients were randomized in a 1:1 ratio to receive selumetinib, 75 mg orally twice daily on a continual basis (n = 50), or chemotherapy (temozolomide, 150 mg/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days [investigator choice]; n = 51) until disease progression, death, intolerable adverse effects, or withdrawal of consent. 

 

 

Median progression-free survival among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) and among those randomized to selumetinib was 15.9 weeks (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P < .001). Median overall survival time was 9.1 months (95% CI, 6.1-11.1 months) with chemotherapy and 11.8 months (95% CI, 9.8-15.7 months) with selumetinib (hazard ratio, 0.66; 95% CI, 0.41-1.06; P = .09). No objective responses were observed with chemotherapy. Forty-nine percent of patients treated with selumetinib achieved tumor regression, with 14% achieving an objective radiographic response to therapy. Treatment-related adverse events were observed in 97% of patients treated with selumetinib, with 37% requiring at least 1 dose reduction.

Conclusions and Relevance  In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed. Improvement in clinical outcomes was accompanied by a high rate of adverse events.

Scooped by veronica garay
Scoop.it!

Liver Structure and the Flow of Blood and Bile (Master's Project) - YouTube

© 2012 Jessica Holland
more...
No comment yet.
Scooped by veronica garay
Scoop.it!

Liver Transplant Surgery: Dr. Mark Ghobrial - YouTube

This video documents a liver transplant performed by Dr. Mark Ghobrial at The Methodist Hospital in Houston, Texas. This is a photoessay by Dr. Joseph Galati...
more...
No comment yet.
Scooped by veronica garay
Scoop.it!

Trasplante hepático | Dres. E. de Santibáñes, J. Pekolj, M. Ciardullo y F. Mattera (video 11 de 33)

Video en el que se relata un trasplante hepático realizado por los doctores Eduardo de Santibáñez, Juan Pekolj, Miguel Ciardullo y Francisco Mattera. Este vi...
more...
No comment yet.
Scooped by veronica garay
Scoop.it!

segmentación hepática - YouTube

Reconocimiento de los segmentos hepáticos en tomografía. Link Número 1: http://www.radiologyassistant.nl/en/p4375bb8dc241d#i4375bb8dd645f Link Número 2: http...
more...
No comment yet.